Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
Paul McKenzie, CEO & Managing Director at CSL, shared a post on LinkedIn:
“Bleeding Disorders Awareness Month is a time to honor the resilience of those living with inherited bleeding disorders.
At CSL, we take pride in our history of pioneering advancements in the treatment and management of these lifelong, chronic diseases, as well as in our dedication to supporting patients and their caregivers.
In recent years, significant advancements in treatment, including gene therapies, have emerged with the potential to significantly improve the lives of individuals with hemophilia.
We commend the researchers, clinicians, and advocates who have contributed to these important developments.
Gene therapy offers a transformative approach for hemophilia patients by enabling them to produce their own clotting factor, potentially reducing bleeds and eliminating the need for ongoing treatments.
These one-time infusions address the genetic cause of hemophilia and potentially provide improved bleed protection, which can lead to less anxiety and an enhanced quality of life.
See here for the latest news on gene therapy in hemophilia.
We are proud to have brought the first approved gene therapy to people with hemophilia B. Over the past two years, CSL has made progress in expanding access to this therapy in the US and Europe.
This has only been possible through our strong collaboration with patients, national authorities, clinicians, patient advocates and payers.
There is still much work to be done.
We will continue to educate health systems on the value of gene therapy drive innovative access solutions, enable patient identification and education and create new clinical pathways.
We are dedicated to collaborating with community partners to enhance the accessibility of gene therapy for individuals with hemophilia.
Our goal is to provide a wider range of treatment options that address the diverse needs of this population.
For over 50 years, CSL has developed treatments for bleeding disorders and other rare diseases, with input and support from the patient community.
We are committed to innovative solutions that make a lasting impact on the lives of the patients we serve.
Our unwavering support for our patients and the communities that advocate for and treat them remains steadfast.
We stand by you every step of the way.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS